Unregistered Sales of Equity Securities and Use of Proceeds.
−Removed: See the disclosure in “Liquidity and Capital Resources - Committed Equity Facility - March 28, 2022” under Item
−Removed: 2 above and in the Current Report on Form 8-K filed by us with the SEC on April 1, 2022, each of which is incorporated herein by reference,
−Removed: for a description of the committed equity facility with Cantor and the shares issuable to Cantor thereunder.
−Removed: addition, effective as of August 25, 2022, we issued 82,618 shares of our common stock to an entity designated by RDx, in satisfaction
−Removed: of a $250,000 installment payment due under the asset purchase agreement dated February 25, 2022, between LucidDx Labs (our wholly-owned
−Removed: subsidiary) and RDx, and unrelated third-party.
−Removed: See the Current Report on Form 8-K filed by us with the SEC on March 3, 2022, which is
−Removed: incorporated herein by reference, for a fuller description of the asset purchase agreement with RDx and the installment payments thereunder.
+Added: as previously disclosed in our current reports on Form 8-K, we did not sell any unregistered securities or repurchase any of our securities
+Added: during the three months ended March 31, 2023.
October 14, 2021, we completed our initial public offering (“IPO”) of our common stock under an effective registration statement
on Form S-1 (SEC File No.
−Removed: As of September 30, 2022, of the net proceeds of $64.4 million, approximately $39.3 million has
−Removed: been used, in a manner consistent with the use of proceeds set forth in the prospectus for our IPO, as follows:
−Removed: approximately $5.3 million
−Removed: of net repayments due to PAVmed;
−Removed: approximately $4.7 million for the purchase of our laboratory equipment, software, and its operating
+Added: As of March 31, 2023, of the net proceeds of $64.4 million, approximately $50.6 million
+Added: has been used, in a manner consistent with the use of proceeds set forth in the prospectus for our IPO, as follows:
+Added: approximately $5.3
+Added: million of net repayments of Due To:
+Added: approximately $5.0 million for the purchase of our laboratory equipment, software,
+Added: and its operating expenses;
and $40.3 million of working capital expenditures.
−Removed: None of the proceeds have been paid to any of our directors, officers, 10%
−Removed: stockholders, or affiliates, other than as described above.
+Added: None of the proceeds have been paid to any of our
+Added: directors, officers, 10% stockholders, or affiliates, other than as described above.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.